Bharat Biotech's nasal vaccine gets approval for Phase II and III clinical trials
by Swadeshi Samachar Swadeshi SamacharBharat
Biotech's Nasal Vaccine has been approved for Phase II and III clinical trials.
Nasal Vaccine: The first nasal (given via nasal spray) vaccine developed by
Bharat Biotech against Kovid-19 has been approved for the second, third phase
of experimental trials. The Department of Biotechnology has given this
information. The first phase of the trial has been done on people between
the ages of 18 and 60, the statement said.
The intranasal vaccine is BBV154, the technology
of which was acquired by Bharat Biotech from Washington University in St.
Louis. This is the first such Kovid-19 vaccine that will have clinical
trials on humans in India.
If you want to Read Breaking news in Hindi like this then check it out
DBT said, "The company has informed that
the vaccine doses administered to healthy participants in the first phase of
clinical trials have been well accepted by the body. No serious adverse
effects are known.” The vaccine was found to be safe even in prior clinical
studies. In animal studies, the vaccine was successful in producing high
levels of antibodies.
read More;- Bollywood news in Hindi
Let us inform that at present, three vaccines
are available in the country for the common people, Bharat Biotech's Covaccine,
Serum Institute's Kovishield and Russia's Sputnik V. The government has
also approved Moderna's mRNA vaccine and Johnson & Johnson's single dose
vaccine for use.
So far 52.95 crore doses of anti-corona vaccine
have been given in the country. According to the Ministry of Health, on
Thursday, 27,83,649 people in the age group of 18 to 44 years were given the
first dose and 4,85,193 were given the second dose.
Sponsor Ads
Created on Aug 13th 2021 10:53. Viewed 257 times.